+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06827262

Real-World Outcomes of Intracept10 Intraosseous Nerve Ablation for Vertebrogenic Back Pain

Led by Boston Scientific Corporation · Updated on 2026-10-09

1500

Participants Needed

22

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are collecting real-world data on the use of the commercially approved Intracept10 Intraosseous Nerve Ablation Systems to treat patients diagnosed with vertebrogenic pain, including those with chronic low-back pain and vertebrogenic pain syndrome. The study aims to better understand outcomes from this minimally invasive procedure in routine clinical settings. Participants will receive treatment with the Intracept10 Intraosseous Nerve Ablation device following local instructions for use. The study observes patients who undergo this nerve ablation therapy without assigning participants to different groups, as it is an observational study without randomization or placebo. Throughout the study, participants will be monitored over 60 months after the procedure. Researchers will assess changes in disability using the Oswestry Disability Index ODI and gather other outcome data to evaluate the impact of treatment. Participation involves regular follow-up to document treatment effects and safety over time.

CONDITIONS

Brief Title

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Research Team

A

Ann Yamano

D

Diane Keesey

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here